Mammalian Fbh1 is important to restore normal mitotic progression following decatenation stress

DNA Repair

Volumn 9, Issue 6, 2010, Pages 708-717

  Laulier, Corentin ^a   Cheng, Anita ^a   Huang, Nick ^a   Stark, Jeremy M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Bisdioxopiperazine; Decatenation; Fbh1; Mitosis; Rad51; Topoisomerase

Indexed keywords

DNA; F BOX PROTEIN; GYRASE INHIBITOR; HELICASE; PIPERAZINEDIONE; RAD51 PROTEIN; UBIQUITIN PROTEIN LIGASE; 4,4'-(1,2-DIMETHYL-1,2-ETHANEDIYL)BIS-2,6-PIPERAZINEDIONE; CATENATED DNA; DNA HELICASE; DNA TOPOISOMERASE (ATP HYDROLYSING); FBXO18 PROTEIN, MOUSE; PIPERAZINE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ANAPHASE; ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL LINE; CELL STRESS; CHROMOSOME BREAKAGE; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; EMBRYO; GENE DELETION; GENE DISRUPTION; HOMOZYGOSITY; MAMMAL; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOCATALYSIS; CELL NUCLEUS; CELL SURVIVAL; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; EMBRYONIC STEM CELL; GENETICS; HOMOZYGOTE; HUMAN; METABOLISM; PHYSIOLOGICAL STRESS; PHYSIOLOGY; PROTEIN TRANSPORT;

ANAPHASE; ANIMALS; BIOCATALYSIS; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CHROMOSOME BREAKAGE; DNA HELICASES; DNA TOPOISOMERASES, TYPE II; DNA, CATENATED; EMBRYONIC STEM CELLS; GENE DELETION; HOMOZYGOTE; HUMANS; MICE; MITOSIS; PIPERAZINES; PROTEIN TRANSPORT; RAD51 RECOMBINASE; STRESS, PHYSIOLOGICAL; F-BOX PROTEINS; TOPOISOMERASE II INHIBITORS;

MAMMALIA; VERTEBRATA;

EID: 77952581198     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2010.03.011     Document Type: Article

References (51)

1. Skowyra D., Craig K.L., Tyers M., Elledge S.J., and Harper J.W. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91 (1997) 209-219
2. Jin J., Cardozo T., Lovering R.C., Elledge S.J., Pagano M., and Harper J.W. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 18 (2004) 2573-2580
3. Kim J., Kim J.H., Lee S.H., Kim D.H., Kang H.Y., Bae S.H., Pan Z.Q., and Seo Y.S. The novel human DNA helicase hFBH1 is an F-box protein. J Biol Chem 277 (2002) 24530-24537
4. Kim J.H., Kim J., Kim D.H., Ryu G.H., Bae S.H., and Seo Y.S. SCFhFBH1 can act as helicase and E3 ubiquitin ligase. Nucleic Acids Res 32 (2004) 2287-2297
5. Lorenz A., Osman F., Folkyte V., Sofueva S., and Whitby M.C. Fbh1 limits Rad51-dependent recombination at blocked replication forks. Mol Cell Biol (2009)
6. Morishita T., Furukawa F., Sakaguchi C., Toda T., Carr A.M., Iwasaki H., and Shinagawa H. Role of the Schizosaccharomyces pombe F-Box DNA helicase in processing recombination intermediates. Mol Cell Biol 25 (2005) 8074-8083
7. Osman F., Dixon J., Barr A.R., and Whitby M.C. The F-Box DNA helicase Fbh1 prevents Rhp51-dependent recombination without mediator proteins. Mol Cell Biol 25 (2005) 8084-8096
8. Chiolo I., Saponaro M., Baryshnikova A., Kim J.H., Seo Y.S., and Liberi G. The human F-Box DNA helicase FBH1 faces Saccharomyces cerevisiae Srs2 and postreplication repair pathway roles. Mol Cell Biol 27 (2007) 7439-7450
9. Lawrence C.L., Jones N., and Wilkinson C.R. Stress-induced phosphorylation of S. pombe Atf1 abrogates its interaction with F box protein Fbh1. Curr Biol 19 (2009) 1907-1911
10. Kohzaki M., Hatanaka A., Sonoda E., Yamazoe M., Kikuchi K., Vu Trung N., Szuts D., Sale J.E., Shinagawa H., Watanabe M., and Takeda S. Cooperative roles of vertebrate Fbh1 and Blm DNA helicases in avoidance of crossovers during recombination initiated by replication fork collapse. Mol Cell Biol 27 (2007) 2812-2820
11. Fugger K., Mistrik M., Danielsen J.R., Dinant C., Falck J., Bartek J., Lukas J., and Mailand N. Human Fbh1 helicase contributes to genome maintenance via pro- and anti-recombinase activities. J Cell Biol 186 (2009) 655-663
12. Daniels M.J., Wang Y., Lee M., and Venkitaraman A.R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306 (2004) 876-879
13. Ryser S., Dizin E., Jefford C.E., Delaval B., Gagos S., Christodoulidou A., Krause K.H., Birnbaum D., and Irminger-Finger I. Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. Cancer Res 69 (2009) 1125-1134
14. Lou Z., Minter-Dykhouse K., and Chen J. BRCA1 participates in DNA decatenation. Nat Struct Mol Biol 12 (2005) 589-593
15. Chan K.L., North P.S., and Hickson I.D. BLM is required for faithful chromosome segregation and its localization defines a class of ultrafine anaphase bridges. EMBO J 26 (2007) 3397-3409
16. Freed E., Lacey K.R., Huie P., Lyapina S.A., Deshaies R.J., Stearns T., and Jackson P.K. Components of an SCF ubiquitin ligase localize to the centrosome and regulate the centrosome duplication cycle. Genes Dev 13 (1999) 2242-2257
17. Korzeniewski N., Zheng L., Cuevas R., Parry J., Chatterjee P., Anderton B., Duensing A., Munger K., and Duensing S. Cullin 1 functions as a centrosomal suppressor of centriole multiplication by regulating polo-like kinase 4 protein levels. Cancer Res 69 (2009) 6668-6675
18. Kops G.J., Weaver B.A., and Cleveland D.W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5 (2005) 773-785
19. Damelin M., and Bestor T.H. The decatenation checkpoint. Br J Cancer 96 (2007) 201-205
20. Baxter J., and Diffley J.F. Topoisomerase II inactivation prevents the completion of DNA replication in budding yeast. Mol Cell 30 (2008) 790-802
21. Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., Cohen G.I., Emami B., Gradishar W.J., Mitchell R.B., Thigpen J.T., Trotti III A., von Hoff D., and Schuchter L.M. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27 (2009) 127-145
22. Nitiss J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9 (2009) 338-350
23. Downes C.S., Clarke D.J., Mullinger A.M., Gimenez-Abian J.F., Creighton A.M., and Johnson R.T. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372 (1994) 467-470
24. Skoufias D.A., Lacroix F.B., Andreassen P.R., Wilson L., and Margolis R.L. Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Mol Cell 15 (2004) 977-990
25. Clarke D.J., Johnson R.T., and Downes C.S. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks. J Cell Sci 105 Pt 2 (1993) 563-569
26. Damelin M., Sun Y.E., Sodja V.B., and Bestor T.H. Decatenation checkpoint deficiency in stem and progenitor cells. Cancer Cell 8 (2005) 479-484
27. Gorbsky G.J. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1, 2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane). Cancer Res 54 (1994) 1042-1048
28. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
29. Hoch R.V., and Soriano P. Context-specific requirements for Fgfr1 signaling through Frs2 and Frs3 during mouse development. Development 133 (2006) 663-673
30. Stark J.M., and Jasin M. Extensive loss of heterozygosity is suppressed during homologous repair of chromosomal breaks. Mol Cell Biol 23 (2003) 733-743
31. Bennardo N., Cheng A., Huang N., and Stark J.M. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 4 (2008) e1000110
32. Moynahan M.E., Pierce A.J., and Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7 (2001) 263-272
33. Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., Kim S.T., Lane W.S., Kastan M.B., and D'Andrea A.D. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109 (2002) 459-472
34. Kanda T., Sullivan K.F., and Wahl G.M. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol 8 (1998) 377-385
35. Sung P., Krejci L., Van Komen S., and Sehorn M.G. Rad51 recombinase and recombination mediators. J Biol Chem 278 (2003) 42729-42732
36. Cardozo T., and Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 5 (2004) 739-751
37. Hasinoff B.B., Kuschak T.I., Yalowich J.C., and Creighton A.M. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50 (1995) 953-958
38. Tanabe K., Ikegami Y., Ishida R., and Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51 (1991) 4903-4908
39. Nitiss J.L. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9 (2009) 327-337
40. Chen X.G., Li Y., Zang M.X., Pei X.R., Xu Y.J., and Gao L.F. cDNA cloning and expression analysis of mouse gene encoding the protein Ercc6l which is a novel member of SNF2 family. Prog Biochem Biophys 31 (2004) 443-448
41. Baumann C., Korner R., Hofmann K., and Nigg E.A. PICH, a Centromere-Associated SNF2 Family ATPase, is regulated by Plk1 and required for the spindle checkpoint. Cell 128 (2007) 101-114
42. Spence J.M., Phua H.H., Mills W., Carpenter A.J., Porter A.C., and Farr C.J. Depletion of topoisomerase IIalpha leads to shortening of the metaphase interkinetochore distance and abnormal persistence of PICH-coated anaphase threads. J Cell Sci 120 (2007) 3952-3964
43. Ishida R., Miki T., Narita T., Yui R., Sato M., Utsumi K.R., Tanabe K., and Andoh T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51 (1991) 4909-4916
44. Fenech M. Cytokinesis-block micronucleus assay evolves into a "cytome" assay of chromosomal instability, mitotic dysfunction and cell death. Mutat Res 600 (2006) 58-66
45. Norppa H., and Falck G.C. What do human micronuclei contain?. Mutagenesis 18 (2003) 221-233
46. Ayoub N., Rajendra E., Su X., Jeyasekharan A.D., Mahen R., and Venkitaraman A.R. The carboxyl terminus of Brca2 links the disassembly of Rad51 complexes to mitotic entry. Curr Biol (2009)
47. Adachi N., Suzuki H., Iiizumi S., and Koyama H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J Biol Chem 278 (2003) 35897-35902
48. Wray J., Williamson E.A., Royce M., Shaheen M., Beck B.D., Lee S.H., Nickoloff J.A., and Hromas R. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells. PLoS One 4 (2009) e5323
49. Ishida R., Sato M., Narita T., Utsumi K.R., Nishimoto T., Morita T., Nagata H., and Andoh T. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol 126 (1994) 1341-1351
50. Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci 121 Suppl. 1 (2008) 1-84
51. Deming P.B., Cistulli C.A., Zhao H., Graves P.R., Piwnica-Worms H., Paules R.S., Downes C.S., and Kaufmann W.K. The human decatenation checkpoint. Proc Natl Acad Sci USA 98 (2001) 12044-12049